JERUSALEM — Teva Pharmaceutical Industries on Monday announced a new organizational structure and executive positions. The changes, which will become effective July 1, are designed to improve global integration and effectiveness across the company, Teva said.
Beginning next month, the company will be led by two commercial business units: global specialty medicines (GSM), established in April 2013; and global generic medicines group (GGM).
GGM will have full global responsibility for all generic markets. It also will be responsible for the company's growing OTC business. Sigurdur Olafsson has been named president and CEO of the newly formed GGM group. The GSM group, led by Dr. Rob Koremans, will be responsible for the company's specialty medicines business. GSM will continue to drive growth and will introduce new brands through its business initiatives.
“The new organizational structure and leadership team will better position Teva to deliver sustainable growth and create short and long-term value. We must capitalize first on our existing assets and capabilities, and exploit opportunities and synergies emanating from the full integration of all business activities — most importantly, generic and specialty — while leveraging our global R&D and operations capabilities," said Teva's president and CEO, Erez Vigodman.
Teva also established global corporate marketing excellence and communications group and the corporate development, strategy and innovation Ggroup. Iris Beck-Codner was named group EVP, corporate marketing excellence and communications. A leader has not yet been appointed for the corporate development, strategy and innovation group.
Rounding out the leadership changes is the appointment of Eric Drapé as group EVP, global head of quality. Drapé currently serves as head of sterile, respiratory and specialty operations.